Remodeling Synapses: From mice to men
Over the last decade, the synapses that connect neurons have emerged as important therapeutic targets in a host of neurological disorders ranging from autism to Alzheimer’s disease. Synaptic signaling can either excite or inhibit the postsynaptic neuron, and the vast majority of excitatory synapses in the mammalian brain rely on structures called dendritic spines (Figure 1). The 'head' of each dendritic spine contains receptors for the chemical neurotransmitter glutamate, which is released by the presynaptic neuron. Neurons can contain different types of glutamate receptors, but the AMPA-type glutamate receptor (AMPAR) is responsible for the majority of fast synaptic transmission and also controls the strength of the synapse.
Many forms of synaptic plasticity – the process that allows specific synapses to become stronger or weaker over time – rely on the addition and removal of AMPARs (Diering and Huganir, 2018). These changes are often accompanied by an increase or decrease in the size of the dendritic spine head (Matsuzaki et al., 2004). Changes in synapse number or strength are a pathological hallmark of several diseases, including neurodevelopmental disorders and Alzheimer’s disease (Forrest et al., 2018), which means that molecules that can consistently modify synapses are attractive as potential therapeutics. Among the most promising of these is a derivative of vitamin A called all-trans retinoic acid, which can potently increase synaptic strength in cultured rodent neurons (Aoto et al., 2008). This molecule appears to function as part of a homeostatic pathway that engages the protein translation machinery in dendritic spines to increase the strength of synapses when synaptic input drops (Jakawich et al., 2010; Wang et al., 2011).
Since all-trans retinoic acid is a potent synaptic regulator with a well-defined mechanism of action, it offers tremendous promise to guide therapeutic development for disorders characterized by synaptic dysfunction. But the critical question is whether these effects and mechanisms are readily translatable to the human brain. Now, in eLife, Andreas Vlachos of the University of Freiburg and colleagues – including Maximilian Lenz as first author – report striking parallels between human and rodent neurons in the synaptic effects of all-trans retinoic acid (Lenz et al., 2021).
The researchers prepared slices from surgically resected brain tissue from patients undergoing neurosurgery to ask whether all-trans retinoic acid has the same effects on human pyramidal neurons from layer 2/3 of the cortex as it has on rodent neurons. They found that the molecule enhanced synaptic currents, without altering many other features of neuronal excitability. Along with these changes, Lenz et al. found that all-trans retinoic acid drove enlargement of dendritic spine heads, but the overall density of dendritic spines did not change: this suggests that all-trans retinoic acid drives AMPAR accumulation and structural plasticity at pre-existing synaptic sites. Finally, Lenz et al. demonstrated that the changes in synaptic strength induced by all-trans retinoic acid in human neurons depended on mRNA translation but not on transcription, a mechanistic signature first seen in rodent neurons.
Next, Lenz et al. – who are based at the University of Freiburg and Goethe-University Frankfurt – explored the relationship between synaptic modulation by all-trans retinoic acid and the spine apparatus, an organelle that is present in a subset of dendritic spines and whose function has remained enigmatic (Jedlicka and Deller, 2017). They found that all-trans retinoic acid enlarged the spine apparatus and, strikingly, that the cross-sectional area of the spine apparatus varied with the size of the dendritic spine itself. This suggests that the spine apparatus might have a key role in the modulation of synaptic strength by all-trans retinoic acid.
To test this hypothesis, Lenz et al. examined the effects of all-trans retinoic acid in synaptopodin knockout mice, which lack the spine apparatus. They found that all-trans retinoic acid did not enhance synaptic currents in cortical pyramidal neurons in the knockout mice; however, when synaptopodin was reintroduced, all-trans retinoic acid was able to increase synaptic currents. Curiously, losing the spine apparatus did not prevent all-trans retinoic acid from enlarging dendritic spines, even though spine size was reduced in the synaptopodin knockout mice.
These results suggest that the spine apparatus helps regulate synaptic architecture, but that all-trans retinoic acid can induce structural remodeling of synapses independently of this organelle. This finding was particularly intriguing because the enlargement of spines and the enhancement of synaptic function often go hand-in-hand. These results underscore the fact that while morphological and functional changes are highly coordinated at cortical synapses, they likely rely on distinct mechanistic pathways.
These results provide a clear answer as to whether the effects of all-trans retinoic acid in rodents can be translated to humans. The molecule is a potent regulator of excitatory synapses in human cortical neurons and uses a mechanism for synaptic regulation that appears largely conserved from rodents to humans. The work of Lenz et al. also raises some important questions about the role of the spine apparatus in the regulation of synapses by all-trans retinoic acid in particular, and by other modulators more generally.
It is tempting to speculate that the spine apparatus may be part of a satellite secretory pathway that delivers locally-translated membrane proteins, such as AMPARs, in dendrites. However, future studies are needed to address the specific role of the spine apparatus relative to other secretory mechanisms that might also operate in dendrites (Pierce et al., 2001; Mikhaylova et al., 2016).
References
-
Dendritic structural plasticity and neuropsychiatric diseaseNature Reviews Neuroscience 19:215–234.https://doi.org/10.1038/nrn.2018.16
Article and author information
Author details
Publication history
Copyright
© 2021, Althaus and Sutton
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 975
- views
-
- 89
- downloads
-
- 1
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Immunology and Inflammation
- Neuroscience
Acute retinal ischemia and ischemia-reperfusion injury are the primary causes of retinal neural cell death and vision loss in retinal artery occlusion (RAO). The absence of an accurate mouse model for simulating the retinal ischemic process has hindered progress in developing neuroprotective agents for RAO. We developed a unilateral pterygopalatine ophthalmic artery occlusion (UPOAO) mouse model using silicone wire embolization combined with carotid artery ligation. The survival of retinal ganglion cells and visual function were evaluated to determine the duration of ischemia. Immunofluorescence staining, optical coherence tomography, and haematoxylin and eosin staining were utilized to assess changes in major neural cell classes and retinal structure degeneration at two reperfusion durations. Transcriptomics was employed to investigate alterations in the pathological process of UPOAO following ischemia and reperfusion, highlighting transcriptomic differences between UPOAO and other retinal ischemia-reperfusion models. The UPOAO model successfully replicated the acute interruption of retinal blood supply observed in RAO. 60 min of Ischemia led to significant loss of major retinal neural cells and visual function impairment. Notable thinning of the inner retinal layer, especially the ganglion cell layer, was evident post-UPOAO. Temporal transcriptome analysis revealed various pathophysiological processes related to immune cell migration, oxidative stress, and immune inflammation during the non-reperfusion and reperfusion periods. A pronounced increase in microglia within the retina and peripheral leukocytes accessing the retina was observed during reperfusion periods. Comparison of differentially expressed genes (DEGs) between the UPOAO and high intraocular pressure models revealed specific enrichments in lipid and steroid metabolism-related genes in the UPOAO model. The UPOAO model emerges as a novel tool for screening pathogenic genes and promoting further therapeutic research in RAO.
-
- Computational and Systems Biology
- Neuroscience
Diffusional kurtosis imaging (DKI) is a methodology for measuring the extent of non-Gaussian diffusion in biological tissue, which has shown great promise in clinical diagnosis, treatment planning, and monitoring of many neurological diseases and disorders. However, robust, fast, and accurate estimation of kurtosis from clinically feasible data acquisitions remains a challenge. In this study, we first outline a new accurate approach of estimating mean kurtosis via the sub-diffusion mathematical framework. Crucially, this extension of the conventional DKI overcomes the limitation on the maximum b-value of the latter. Kurtosis and diffusivity can now be simply computed as functions of the sub-diffusion model parameters. Second, we propose a new fast and robust fitting procedure to estimate the sub-diffusion model parameters using two diffusion times without increasing acquisition time as for the conventional DKI. Third, our sub-diffusion-based kurtosis mapping method is evaluated using both simulations and the Connectome 1.0 human brain data. Exquisite tissue contrast is achieved even when the diffusion encoded data is collected in only minutes. In summary, our findings suggest robust, fast, and accurate estimation of mean kurtosis can be realised within a clinically feasible diffusion-weighted magnetic resonance imaging data acquisition time.